Gabapentin Capsule
Product Images NDC 85509-2180

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 85509-2180). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Phoenix Rx Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (2180 3)

This drug facts panel for Gabapentin Capsules, USP supplies 300 mg per capsule and contains 30 capsules. It includes storage directions to keep at 20° to 25°C with allowable excursions, child-resistant container instructions, reminders to keep medication away from children, and guidance for pharmacists to dispense the Medication Guide. The label references scanning a QR code for full prescribing information and names both the manufacturer, ScieGen Pharmaceuticals, Inc., and the repackager, PHOENIX RX LLC.*

FDA Label Image

Figure 1 (Image 01)

A line graph depicting mean pain scores over 8 weeks during a study with a 4-week dose titration period followed by a 4-week fixed dose period. The graph compares placebo to Gabapentin at 3600 mg/day, showing a decrease in pain score for Gabapentin and stable scores for placebo.*

FDA Label Image

Figure 2 (Image 02)

A line graph depicting the mean pain score over a 7-week period comparing placebo with Gabapentin at doses of 1800 mg/day and 2400 mg/day. The x-axis represents weeks, including a 3-week dose titration period followed by a 4-week fixed dose period, while the y-axis shows the mean pain score ranging from 0 to 10. The graph indicates changes in pain scores for each group across the timeline.*

FDA Label Image

Figure 3 (Image 03)

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) to Gabapentin (GBP) doses in two studies. The chart shows percentages on the vertical axis, with Study 1 illustrating 12% for placebo and 29% for GBP 3600, and Study 2 showing 14% for placebo, 32% for GBP 1800, and 34% for GBP 2400. Statistical significance is indicated by p-values less than 0.01 and 0.001.*

FDA Label Image

Image-04 (Image 04)

A mathematical formula illustrating the calculation of creatinine clearance (CLCr), incorporating variables for age, weight, serum creatinine, and a factor for female patients. The equation is shown within square brackets and includes multiplication and division operations.*

FDA Label Image

Gabapentin Structural Formula (Image 05)

Chemical structure diagram of gabapentin showing its molecular formula arrangement with a cyclohexane ring and amino and carboxylic acid functional groups.*

FDA Label Image

Image-09 (Image 09)

A scatter plot showing the percentage difference on the y-axis and daily dose in milligrams on the x-axis for Gabapentin. Data points from three different studies (Study a, Study b, and Study c) are marked with distinct symbols and demonstrate differences across various doses ranging from 600 mg to 1800 mg.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.